| Year |
Citation |
Score |
| 2019 |
Viarisio D, Robitaille A, Müller-Decker K, Flechtenmacher C, Gissmann L, Tommasino M. Cancer susceptibility of beta HPV49 E6 and E7 transgenic mice to 4-nitroquinoline 1-oxide treatment correlates with mutational signatures of tobacco exposure. Virology. 538: 53-60. PMID 31569015 DOI: 10.1016/j.virol.2019.09.010 |
0.458 |
|
| 2018 |
Viarisio D, Müller-Decker K, Accardi R, Robitaille A, Dürst M, Beer K, Jansen L, Flechtenmacher C, Bozza M, Harbottle R, Voegele C, Ardin M, Zavadil J, Caldeira S, Gissmann L, et al. Beta HPV38 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin carcinogenesis in mice. Plos Pathogens. 14: e1006783. PMID 29324843 DOI: 10.1371/journal.ppat.1006783 |
0.425 |
|
| 2017 |
Viarisio D, Gissmann L, Tommasino M. Human papillomaviruses and carcinogenesis: well-established and novel models. Current Opinion in Virology. 26: 56-62. PMID 28778034 DOI: 10.1016/j.coviro.2017.07.014 |
0.489 |
|
| 2016 |
Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, Gröne HJ, Gheit T, Flechtenmacher C, Gissmann L, Tommasino M. Correction: E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice. Plos Pathogens. 12: e1006005. PMID 27792794 DOI: 10.1371/journal.ppat.1006005 |
0.362 |
|
| 2016 |
Viarisio D, Müller-Decker K, Hassel JC, Alvarez JC, Flechtenmacher C, Pawlita M, Gissmann L, Tommasino M. The BRAF inhibitor vemurafenib enhances UV-induced skin carcinogenesis in beta HPV38 E6 and E7 transgenic mice. The Journal of Investigative Dermatology. PMID 27650607 DOI: 10.1016/j.jid.2016.08.030 |
0.375 |
|
| 2016 |
Viarisio D, Müller-Decker K, Zanna P, Kloz U, Aengeneyndt B, Accardi R, Flechtenmacher C, Gissmann L, Tommasino M. Novel ß-HPV49 Transgenic Mouse Model of Upper Digestive Tract Cancer. Cancer Research. 76: 4216-25. PMID 27216183 DOI: 10.1158/0008-5472.CAN-16-0370 |
0.516 |
|
| 2016 |
López-Toledo G, Schädlich L, Alonso-Castro ÁJ, Monroy-García A, García-Rocha R, Guido MC, Gissmann L, García-Carrancá A. Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model. Viral Immunology. 29: 276-87. PMID 27058179 DOI: 10.1089/vim.2015.0080 |
0.667 |
|
| 2015 |
Kumar A, Hussain S, Sharma G, Mehrotra R, Gissmann L, Das BC, Bharadwaj M. Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: In-silico &in-vivo insight to vaccine development. Scientific Reports. 5: 15751. PMID 26507515 DOI: 10.1038/srep15751 |
0.575 |
|
| 2015 |
Lei J, Osen W, Gardyan A, Hotz-Wagenblatt A, Wei G, Gissmann L, Eichmüller S, Löchelt M. Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy. Plos One. 10: e0138458. PMID 26397953 DOI: 10.1371/journal.pone.0138458 |
0.365 |
|
| 2015 |
Höfler D, Böhmer G, von Wasielewski R, Neumann H, Halec G, Holzinger D, Dondog B, Gissmann L, Pawlita M, Schmitt M. HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in HPV-based cervical cancer precursor screening. Gynecologic Oncology. 138: 676-82. PMID 26148764 DOI: 10.1016/j.ygyno.2015.06.039 |
0.454 |
|
| 2015 |
Kumar A, Hussain S, Yadav IS, Gissmann L, Natarajan K, Das BC, Bharadwaj M. Identification of human papillomavirus-16 E6 variation in cervical cancer and their impact on T and B cell epitopes. Journal of Virological Methods. 218: 51-8. PMID 25800725 DOI: 10.1016/j.jviromet.2015.03.008 |
0.467 |
|
| 2015 |
Gaiser MR, Textor S, Senger T, Schädlich L, Waterboer T, Kaufmann AM, Süsal C, Pawlita M, Enk AH, Gissmann L, Lonsdorf AS. Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. Journal of Dermatological Science. 77: 37-45. PMID 25439730 DOI: 10.1016/j.jdermsci.2014.11.002 |
0.301 |
|
| 2014 |
Almajhdi FN, Senger T, Amer HM, Gissmann L, Öhlschläger P. Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling). Plos One. 9: e113461. PMID 25422946 DOI: 10.1371/journal.pone.0113461 |
0.587 |
|
| 2014 |
Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. The Journal of Pathology. 234: 441-51. PMID 25043390 DOI: 10.1002/path.4405 |
0.489 |
|
| 2014 |
Marcuzzi GP, Awerkiew S, Hufbauer M, Schädlich L, Gissmann L, Eming S, Pfister H. Tumor prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination. Medical Microbiology and Immunology. 203: 155-63. PMID 24446083 DOI: 10.1007/s00430-014-0327-4 |
0.554 |
|
| 2013 |
Viarisio D, Decker KM, Aengeneyndt B, Flechtenmacher C, Gissmann L, Tommasino M. Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesis. The Journal of General Virology. 94: 749-52. PMID 23223623 DOI: 10.1099/vir.0.048991-0 |
0.457 |
|
| 2013 |
Halec G, Schmitt M, Dondog B, Sharkhuu E, Wentzensen N, Gheit T, Tommasino M, Kommoss F, Bosch FX, Franceschi S, Clifford G, Gissmann L, Pawlita M. Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer International Journal of Cancer. 132: 63-71. PMID 22514107 DOI: 10.1002/ijc.27605 |
0.492 |
|
| 2012 |
Kaufmann AM, Gissmann L, Schneider A. The worldwide perspective on human papillomavirus and cervical cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1400-1. PMID 22956725 DOI: 10.1158/1055-9965.EPI-12-0849 |
0.349 |
|
| 2012 |
Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, Müller M, Kellner M, Hörer M, Michaelis U, Roden RB, Gissmann L, Kleinschmidt JA. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. Plos One. 7: e39741. PMID 22761884 DOI: 10.1371/Journal.Pone.0039741 |
0.647 |
|
| 2012 |
Nieto K, Stahl-Hennig C, Leuchs B, Müller M, Gissmann L, Kleinschmidt JA. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Human Gene Therapy. 23: 733-41. PMID 22401308 DOI: 10.1089/Hum.2011.202 |
0.675 |
|
| 2012 |
Gersch ED, Gissmann L, Garcea RL. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antiviral Therapy. 17: 425-34. PMID 22293302 DOI: 10.3851/Imp1941 |
0.581 |
|
| 2011 |
Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, Gröne HJ, Gheit T, Flechtenmacher C, Gissmann L, Tommasino M. E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. Plos Pathogens. 7: e1002125. PMID 21779166 DOI: 10.1371/journal.ppat.1002125 |
0.458 |
|
| 2011 |
Schmitt M, Dalstein V, Waterboer T, Clavel C, Gissmann L, Pawlita M. The HPV16 transcriptome in cervical lesions of different grades. Molecular and Cellular Probes. 25: 260-5. PMID 21664454 DOI: 10.1016/j.mcp.2011.05.003 |
0.462 |
|
| 2011 |
Nieto K, Gissmann L, Schädlich L. Human papillomavirus-specific immune therapy: failure and hope. Antiviral Therapy. 15: 951-7. PMID 21041909 DOI: 10.3851/IMP1665 |
0.525 |
|
| 2011 |
Textor S, Accardi R, Havlova T, Hussain I, Sylla BS, Gissmann L, Cerwenka A. NF-κ B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction. International Journal of Cancer. 128: 1104-13. PMID 20473930 DOI: 10.1002/ijc.25442 |
0.422 |
|
| 2010 |
Schmitt M, Dalstein V, Waterboer T, Clavel C, Gissmann L, Pawlita M. Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Research. 70: 249-56. PMID 20028865 DOI: 10.1158/0008-5472.CAN-09-2514 |
0.459 |
|
| 2010 |
Senger T, Schädlich L, Textor S, Klein C, Michael KM, Buck CB, Gissmann L. Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine. 28: 1583-93. PMID 20003923 DOI: 10.1016/j.vaccine.2009.11.048 |
0.472 |
|
| 2009 |
Nieto K, Kern A, Leuchs B, Gissmann L, Müller M, Kleinschmidt JA. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antiviral Therapy. 14: 1125-37. PMID 20032542 DOI: 10.3851/Imp1469 |
0.66 |
|
| 2009 |
Gissmann L, Nieto K. The therapeutic vaccine: is it feasible? Archives of Medical Research. 40: 493-8. PMID 19853190 DOI: 10.1016/j.arcmed.2009.07.003 |
0.55 |
|
| 2009 |
Gissmann L. HPV vaccines: preclinical development. Archives of Medical Research. 40: 466-70. PMID 19853186 DOI: 10.1016/j.arcmed.2009.07.002 |
0.578 |
|
| 2009 |
Senger T, Becker MR, Schädlich L, Waterboer T, Gissmann L. Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. Journal of Virology. 83: 12692-701. PMID 19793806 DOI: 10.1128/JVI.01582-09 |
0.591 |
|
| 2009 |
Morgenfeld M, Segretin ME, Wirth S, Lentz E, Zelada A, Mentaberry A, Gissmann L, Bravo-Almonacid F. Potato virus X coat protein fusion to human papillomavirus 16 E7 oncoprotein enhance antigen stability and accumulation in tobacco chloroplast. Molecular Biotechnology. 43: 243-9. PMID 19579017 DOI: 10.1007/s12033-009-9195-3 |
0.495 |
|
| 2009 |
Schädlich L, Senger T, Gerlach B, Mücke N, Klein C, Bravo IG, Müller M, Gissmann L. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. Journal of Virology. 83: 7690-705. PMID 19457985 DOI: 10.1128/JVI.02588-08 |
0.317 |
|
| 2009 |
Senger T, Schädlich L, Gissmann L, Müller M. Enhanced papillomavirus-like particle production in insect cells. Virology. 388: 344-53. PMID 19409593 DOI: 10.1016/j.virol.2009.04.004 |
0.618 |
|
| 2009 |
Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Müller M, Ottonello S. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. Vaccine. 27: 1949-56. PMID 19368776 DOI: 10.1016/j.vaccine.2009.01.102 |
0.589 |
|
| 2009 |
Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann L, Müller M, Sacher A, Racz P, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. Plos Pathogens. 5: e1000373. PMID 19360120 DOI: 10.1371/Journal.Ppat.1000373 |
0.485 |
|
| 2009 |
Ohlschläger P, Quetting M, Alvarez G, Dürst M, Gissmann L, Kaufmann AM. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. International Journal of Cancer. Journal International Du Cancer. 125: 189-98. PMID 19358269 DOI: 10.1002/ijc.24333 |
0.337 |
|
| 2009 |
Schädlich L, Senger T, Kirschning CJ, Müller M, Gissmann L. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine. 27: 1511-22. PMID 19174177 DOI: 10.1016/j.vaccine.2009.01.014 |
0.646 |
|
| 2008 |
Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine. K62-7. PMID 18847558 DOI: 10.1016/j.vaccine.2008.05.066 |
0.56 |
|
| 2008 |
Mattil-Fritz S, Scharner D, Piuko K, Thönes N, Gissmann L, Müller H, Müller M. Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles. The Journal of General Virology. 89: 138-147. PMID 18089737 DOI: 10.1099/vir.0.83266-0 |
0.339 |
|
| 2008 |
Leykauf K, Kabsch K, Gassler N, Gissmann L, Alonso A, Schenkel J. Expression of the HPV11 E2 gene in transgenic mice does not result in alterations of the phenotypic pattern. Transgenic Research. 17: 1-8. PMID 17701441 DOI: 10.1007/s11248-007-9130-y |
0.418 |
|
| 2007 |
de Witte L, Zoughlami Y, Aengeneyndt B, David G, van Kooyk Y, Gissmann L, Geijtenbeek TB. Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology. 212: 679-91. PMID 18086370 DOI: 10.1016/j.imbio.2007.09.006 |
0.35 |
|
| 2007 |
Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). International Journal of Cancer. Journal International Du Cancer. 121: 2794-800. PMID 17721997 DOI: 10.1002/ijc.23022 |
0.506 |
|
| 2007 |
Müller M, Gissmann L. A long way: history of the prophylactic papillomavirus vaccine. Disease Markers. 23: 331-6. PMID 17627066 DOI: 10.1155/2007/939634 |
0.318 |
|
| 2007 |
Gissmann L, Müller M. Development of prophylactic HPV vaccines. Collegium Antropologicum. 113-5. PMID 17598512 |
0.627 |
|
| 2007 |
Gasparić M, Rubio I, Thönes N, Gissmann L, Müller M. Prophylactic DNA immunization against multiple papillomavirus types. Vaccine. 25: 4540-53. PMID 17485151 DOI: 10.1016/j.vaccine.2007.04.001 |
0.692 |
|
| 2007 |
Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. Journal of Immunology (Baltimore, Md. : 1950). 178: 3186-97. PMID 17312167 |
0.555 |
|
| 2006 |
Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. S3/1-10. PMID 16949995 DOI: 10.1016/j.vaccine.2006.05.115 |
0.448 |
|
| 2006 |
Samorski R, Gissmann L, Osen W. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. Immunology Letters. 107: 41-9. PMID 16949679 DOI: 10.1016/j.imlet.2006.07.003 |
0.369 |
|
| 2006 |
Kuck D, Lau T, Leuchs B, Kern A, Müller M, Gissmann L, Kleinschmidt JA. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. Journal of Virology. 80: 2621-30. PMID 16501072 DOI: 10.1128/Jvi.80.6.2621-2630.2006 |
0.65 |
|
| 2006 |
Ohlschläger P, Pes M, Osen W, Dürst M, Schneider A, Gissmann L, Kaufmann AM. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine. 24: 2880-93. PMID 16472545 DOI: 10.1016/j.vaccine.2005.12.061 |
0.513 |
|
| 2006 |
Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. Journal of Clinical Microbiology. 44: 504-12. PMID 16455905 DOI: 10.1128/JCM.44.2.504-512.2006 |
0.44 |
|
| 2006 |
Kuck D, Leder C, Kern A, Müller M, Piuko K, Gissmann L, Kleinschmidt JA. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly. Vaccine. 24: 2952-65. PMID 16414157 DOI: 10.1016/J.Vaccine.2005.12.023 |
0.673 |
|
| 2006 |
Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, Gabet AS, Sylla BS, Gissmann L, Hainaut P, Tommasino M. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. Embo Reports. 7: 334-40. PMID 16397624 DOI: 10.1038/sj.embor.7400615 |
0.429 |
|
| 2006 |
Dong W, Kloz U, Accardi R, Caldeira S, Tong WM, Wang ZQ, Jansen L, Dürst M, Sylla BS, Gissmann L, Tommasino M. Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. Journal of Virology. 79: 14899-908. PMID 16282489 DOI: 10.1128/JVI.79.23.14899-14908.2005 |
0.481 |
|
| 2006 |
Dell K, Koesters R, Gissmann L. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. International Journal of Cancer. 118: 364-72. PMID 16052529 DOI: 10.1002/ijc.21360 |
0.382 |
|
| 2005 |
Dell K, Koesters R, Linnebacher M, Klein C, Gissmann L. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine. 24: 2238-47. PMID 16455165 DOI: 10.1016/j.vaccine.2005.11.060 |
0.597 |
|
| 2005 |
Steinberg T, Ohlschläger P, Sehr P, Osen W, Gissmann L. Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine. 23: 1149-57. PMID 15629358 DOI: 10.1016/j.vaccine.2004.08.027 |
0.533 |
|
| 2004 |
Freyschmidt EJ, Alonso A, Hartmann G, Gissmann L. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antiviral Therapy. 9: 479-89. PMID 15456078 |
0.524 |
|
| 2004 |
Mossadegh N, Gissmann L, Müller M, Zentgraf H, Alonso A, Tomakidi P. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology. 326: 57-66. PMID 15262495 DOI: 10.1016/j.virol.2004.04.050 |
0.489 |
|
| 2004 |
Braun K, Ehemann V, Waldeck W, Pipkorn R, Corban-Wilhelm H, Jenne J, Gissmann L, Debus J. HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs). Cancer Letters. 209: 37-49. PMID 15145519 DOI: 10.1016/j.canlet.2004.02.022 |
0.409 |
|
| 2003 |
Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Müller M, Pawlita M, Schäfer K, Sehr P, Staib C, Sutter G, Gissmann L. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. Journal of Virology. 77: 4635-45. PMID 12663770 DOI: 10.1128/Jvi.77.8.4635-4645.2003 |
0.678 |
|
| 2002 |
Michel N, Osen W, Gissmann L, Schumacher TNM, Zentgraf H, Müller M. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology. 294: 47-59. PMID 11886264 DOI: 10.1006/Viro.2001.1321 |
0.532 |
|
| Show low-probability matches. |